REG - Allergy Therapeutics - Grass MATA MPL Phase III data published in Allergy

Allergy TherapeuticsAnnouncement

17/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250217:nRSQ2397Xa&default-theme=true

RNS Number : 2397X  Allergy Therapeutics PLC  17 February 2025

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

 

Allergy Therapeutics announces publication of Grass MATA MPL Phase III data in
the journal Allergy

 

17 February 2025 Allergy Therapeutics (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy immunotherapies,
today announces the publication
(https://onlinelibrary.wiley.com/doi/full/10.1111/all.16491) of comprehensive
data from its pivotal G306 Phase III trial of Grass MATA MPL, the Group's
innovative subcutaneous immunotherapy (SCIT) candidate designed to address
the cause of symptoms of allergic rhinoconjunctivitis due grass pollen, in the
journal Allergy.

 

The successful G306 Phase III trial, which completed in November 2023
(https://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=15929578)
, met its primary endpoint, demonstrating a highly statistically significant
reduction in the Combined Symptom & Medication Score (CSMS) of 20.3%
(p=0.0005) compared to placebo over the peak pollen season. The trial's
results supported the recent submission
(https://www.londonstockexchange.com/news-article/AGY/submission-of-maa-for-grass-mata-mpl/16778898)
of a Marketing Authorisation Application to the Paul Ehrlich Institut in
Germany.

 

Grass MATA MPL is an aluminium-free, pre-seasonal short-course immunotherapy
designed to address the cause of symptoms of allergic rhinoconjunctivitis due
to grass pollen, using just six injections prior to the grass allergy season.

 

The publication includes new mechanistic insights into Grass MATA MPL's mode
of action, supplementing the previously reported positive efficacy and safety
data:

 

·      The study reveals how Grass MATA MPL works at a molecular level,
showing it triggers multiple protective immune responses through the induction
of both IgG4 and IgA (specifically IgA1 and IgA2) antibodies - a more
comprehensive immunological effect than seen with other allergy treatments.

 

·      Newly published comparative analysis reveals that no other
subcutaneous immunotherapy for respiratory allergies has achieved greater than
14% efficacy improvement in Phase III trials over the past decade -
highlighting the significance of Grass MATA MPL's previously reported
(https://www.londonstockexchange.com/news-article/AGY/further-detail-from-g306-phase-iii-field-trial/16456071)
20.3% improvement over placebo.

 

·      Patients reported significantly better rhinitis quality of life
while using Grass MATA MPL, with a 27.7% improvement compared to placebo -
notably higher than achieved with other grass immunotherapy products.

 

·      The publication provides new context showing how Grass MATA MPL's
six-injection format, which achieved >95% trial completion, contrasts
favourably with traditional immunotherapy treatments requiring up to 100
injections or daily tablets over several years with higher discontinuation
rates.

 

Professor Stefan Zielen, lead author and Principal Investigator from Goethe
University, Frankfurt, said: "These comprehensive findings represent an
important advance in allergy immunotherapy research. The data demonstrate that
Grass MATA MPL stimulates a broader protective immune response than we
typically see, activating multiple antibody pathways that help reduce allergic
reactions. This deeper understanding of the treatment candidate's mode of
action helps explain the strong efficacy we observed in the Phase III trial
and, importantly, the significant improvements patients reported in their
daily lives."

 

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented:
"The publication of our G306 data in Allergy, one of the world's leading
allergy journals, provides important validation of our innovative approach to
allergy immunotherapy. These results reinforce our confidence in Grass MATA
MPL's potential to provide an important new treatment option for patients
affected by seasonal grass allergy."

 

 

- ENDS -

 

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries in nine major European countries and via distribution agreements
in an additional ten countries. For more information, please see
www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

About Grass MATA MPL

Grass MATA MPL is being developed as a pre-seasonal subcutaneous immunotherapy
product for the treatment of allergic rhinitis and/or rhinoconjunctivitis.

 

Grass MATA MPL contains an extract of 13 grass pollens modified with
glutaraldehyde to form allergoids that reduces the reactivity with
immunoglobulin E (IgE) antibodies without a reduction in other important
immunological properties, such as T-cell reactivity. The allergoid is adsorbed
to microcrystalline tyrosine as a depot adjuvant system formulation.
Monophosphoryl lipid-A (MPL), is included as an adjuvant to increase the
immunogenic effect of the immunotherapy and to enhance the switch from an
allergen specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1)
like immune response.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCTIMFTMTBBBTA